Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
Identifieur interne : 000038 ( Main/Exploration ); précédent : 000037; suivant : 000039Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
Auteurs : Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]Source :
- Rheumatology (Oxford, England) [ 1462-0332 ] ; 2020.
Abstract
For decades, the treatment of GCA has relied on glucocorticoids. Work over the past two decades has supported a modest efficacy of MTX but no clear benefit from anti-TNF-based therapies. More recently, the therapeutic armamentarium for GCA has expanded. The availability of agents targeting specific cytokines, cytokine receptors or signalling pathways, along with a better, although still limited, understanding of the immunopathology of GCA, are opening further therapeutic possibilities. Blocking IL-6 receptor with tocilizumab has been effective in maintaining remission and reducing glucocorticoid exposure and tocilizumab has been approved for the treatment of GCA. However, nearly half of the patients do not benefit from tocilizumab and additional options need to be investigated. This review focuses on standard therapeutic approaches and on targeted therapies that have been or are currently under investigation.
DOI: 10.1093/rheumatology/kez645
PubMed: 32348525
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000006
- to stream PubMed, to step Curation: 000006
- to stream PubMed, to step Checkpoint: 000021
- to stream Ncbi, to step Merge: 002C96
- to stream Ncbi, to step Curation: 002C96
- to stream Ncbi, to step Checkpoint: 002C96
- to stream Main, to step Merge: 000038
- to stream Main, to step Curation: 000038
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.</title><author><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rios Garces, Roberto" sort="Rios Garces, Roberto" uniqKey="Rios Garces R" first="Roberto" last="Ríos-Garcés">Roberto Ríos-Garcés</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32348525</idno><idno type="pmid">32348525</idno><idno type="doi">10.1093/rheumatology/kez645</idno><idno type="wicri:Area/PubMed/Corpus">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000006</idno><idno type="wicri:Area/PubMed/Curation">000006</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000006</idno><idno type="wicri:Area/PubMed/Checkpoint">000021</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000021</idno><idno type="wicri:Area/Ncbi/Merge">002C96</idno><idno type="wicri:Area/Ncbi/Curation">002C96</idno><idno type="wicri:Area/Ncbi/Checkpoint">002C96</idno><idno type="wicri:Area/Main/Merge">000038</idno><idno type="wicri:Area/Main/Curation">000038</idno><idno type="wicri:Area/Main/Exploration">000038</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.</title><author><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Rios Garces, Roberto" sort="Rios Garces, Roberto" uniqKey="Rios Garces R" first="Roberto" last="Ríos-Garcés">Roberto Ríos-Garcés</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><affiliation wicri:level="3"><nlm:affiliation>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona. Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><series><title level="j">Rheumatology (Oxford, England)</title><idno type="eISSN">1462-0332</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For decades, the treatment of GCA has relied on glucocorticoids. Work over the past two decades has supported a modest efficacy of MTX but no clear benefit from anti-TNF-based therapies. More recently, the therapeutic armamentarium for GCA has expanded. The availability of agents targeting specific cytokines, cytokine receptors or signalling pathways, along with a better, although still limited, understanding of the immunopathology of GCA, are opening further therapeutic possibilities. Blocking IL-6 receptor with tocilizumab has been effective in maintaining remission and reducing glucocorticoid exposure and tocilizumab has been approved for the treatment of GCA. However, nearly half of the patients do not benefit from tocilizumab and additional options need to be investigated. This review focuses on standard therapeutic approaches and on targeted therapies that have been or are currently under investigation.</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Cid, Maria C" sort="Cid, Maria C" uniqKey="Cid M" first="Maria C" last="Cid">Maria C. Cid</name></region><name sortKey="Espigol Frigole, Georgina" sort="Espigol Frigole, Georgina" uniqKey="Espigol Frigole G" first="Georgina" last="Espígol-Frigolé">Georgina Espígol-Frigolé</name><name sortKey="Rios Garces, Roberto" sort="Rios Garces, Roberto" uniqKey="Rios Garces R" first="Roberto" last="Ríos-Garcés">Roberto Ríos-Garcés</name><name sortKey="Terrades Garcia, Nekane" sort="Terrades Garcia, Nekane" uniqKey="Terrades Garcia N" first="Nekane" last="Terrades-García">Nekane Terrades-García</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000038 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000038 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32348525
|texte= Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32348525" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |